Consistent with this observation, in a propensity-matched analysis using real-world data from two USA patient cohorts, SGLT2 inhibitors use reduced the risk of AKI by between 50 and 60% (unadjusted HRs) (75), and in the EMPRISE observational study, treatment with empagliflozin was associated with a 46% lower risk of AKI requiring dialysis (76). Here, SLC5A2 is linked to acute kidney injury.